STL Index for: Clindamycin

This review details the rosacea phenotype approach to diagnosis and classification, and summarizes current evidence-based treatment recommendations for individual features.

In this article, we provide a guide to address a growing need by primary care physicians to have a logical and practical approach to treating various forms of acne.

The focus of this review is to delve deeper into the use of Biacna® Gel, a fixed-dose clindamycin/tretinoin combination product, for the treatment of acne.

Acne is among the most common dermatological conditions seen in primary care. In this article, we provide a guide to address a growing need by primary care physicians to have a logical and practical approach to treating various forms of acne.

For the purposes of this article, the focus will be on the topical treatment of post-adolescent mild to moderate acne. A selection of over-the-counter and prescription based topical treatments are discussed below.

Physicians will be particularly reassured if the suggested guidelines are supported by scientific evidence. This new Canadian clinical guideline for the treatment of acne was developed taking into account new data published up to March 2015, as well as expert opinion and clinical experience.

Hidradenitis suppurativa (HS) is a chronic disease of the follicular unit that often leads to marked impairment of quality of life. This article reviews various treatment modalities for HS including laser, surgery, retinoids, immunosuppression, biologics, and antibiotics.

Acne vulgaris is a multifactorial disease characterized by different types of lesions at various stages of development. Treatment options, such as light based therapy and systemic therapy, as well as CIS-Isotretinoin (Epuris™) that increases absorption are discussed as well as patient adherence.

Acne vulgaris is a multifactorial disease characterized by different types of lesions at various stages of development. The most frequently used therapeutic agents for acne are topical. This article focuses on the role of vehicles and advancements in this area.

Administration of antibiotics, often for prolonged periods, has become the standard of care for acne. The authors provide current evidence to suggest that dermatologists should consider a departure from standard operating procedure by curtailing, if not discontinuing, the routine and regular use of antibiotics for acne.

Acne is among the most common dermatological disorders seen by dermatologists, affecting approximately 85% of people between the ages of 12 and 24 years. The use of adjunctive cleansers and moisturizers can help mitigate treatment side effects and subsequently enhance therapeutic efficacy.

Rosacea is a common chronic skin disorder that has significant impact on the quality of life of affected individuals. Research interest has led to the development of other emerging therapies including topical ivermectin, brimonidine and oxymetazoline that hold promise for patients suffering from this condition.

Propionibacterium acnes (P. acnes) is an anaerobic bacteria implicated in the pathogenesis of acne. Current treatment guidelines offer strategies to limit the potential for resistance while achieving optimal outcome in the management of inflammatory and non-inflammatory acne.

Acne vulgaris is the most common skin disorder affecting children and young adults in North America. This article discusses combination therapy, and simplifying treatment plans in order to increase patient adherence, which is often a critical problem in treating acne.

Patient adherence remains a serious challenge with acne patients. This article will review this problem and offer a number of suggestions, including dosing considerations and the use of laser/light devices, to better treat the non-adherent patient.

This article discusses the rationale behind various topical treatments for acne to increase adherence and optimize outcomes. Efficacy, safety, antibiotic resistance, onset of action, and combination therapies are covered.

Acne vulgaris is a common chronic inflammatory cutaneous disease involving the pilosebaceous unit. This article discusses the multifactorial nature of acne pathophysiology, therapeutics, and mechanism of action.

Acne vulgaris is a chronic inflammatory cutaneous disease involving the pilosebaceous unit. This article discusses pathophysiology, sebum production, keratinization, and the role of P.acnes in acne formation.

Acne vulgaris is a common disorder of the pilosebaceous follicle with multiple pathogenic factors. Topics like antibiotic treatment, antibiotic resistant, topical agents, are covered.

This article delves into appropriate use of topical therapies for acne treatment. Appropriate agent selection, tolerance, adherence, follow-up, and considerations like complexity of treatment are discussed.

Acne vulgaris is a disease of the pilosebaceous follicle characterized by non-inflammatory (open and closed comedones) and inflammatory lesions. Its pathogenesis is multifactorial - the interplay of hormonal, bacterial, and immunological (inflammatory) factors results in the formation of acne lesions.

This article reviews the various subtypes of rosacea, their clinical presentations, and the considerations in choosing the optimal therapeutic options. The importance of tailored treatment is discussed as well as topical therapies.

Benzoyl peroxide is one of the most widely used topical agents for acne. This article discusses the anti-inflammatory and comedolytic effects of benzoyl peroxide.

Topical products commonly used to treat acne include retinoids and antimicrobials, due to their effects on different components of pathogenesis. Accordingly, a fixed combination of adapalene 0.1% and benzoyl peroxide (BPO) 2.5% was developed (Epiduo™, Galderma) and was approved by the US FDA for the treatment of acne.

Topical treatment is the mainstay for mild acne, and adjunctive to oral or hormonal therapy for moderate acne. This article explores recent formulary advances and offers clinical strategies that can encourage adherence and improve treatment outcomes.

Many options exist for the treatment of rosacea, including topical and systemic therapies, laser and light-based therapies, and surgical procedures. The goals of therapy include reduction of papules, pustules, erythema, physical discomfort, and an improvement in quality of life.

A vast spectrum of topical anti-acne agents has emerged in response to new insights that have been gained through the understanding of disease pathophysiology and the need for clinicians to adopt an individualized therapeutic approach.

The multifactorial nature of acne vulgaris often requires a combination of topical and/or oral agents for successful management. Common challenges of this multipronged approach include the potential development of skin irritation, which results in nonadherence, as well as concern over bacterial resistance.

This article is an overview of the common topical agents used for treating acne: Benzoyl peroxide, retinoids, topical antibiotics, azelaic acid, and combination products.

Acne vulgaris can represent a therapeutic challenge in terms of managing ongoing symptoms and preventing scar formation. Dermatologists may now have viable new alternatives for treating all grades of acne severity that circumvent the negative side-effects associated with many conventional options.

The epidermal growth factor receptor (EGFR) is often overexpressed or dysregulated in solid tumors. Targeting the EGFR-mediated signaling pathway has become routine practice in the treatment of lung, pancreatic, head and neck, and colon carcinomas.

Since patient compliance is a concern, a great deal of attention must be given to the methods available to minimize the chance of irritation. In the opinion of the author, this may be the single most important factor influencing the success of topical therapy in acne.

An in-depth review of Clindoxyl® Gel (Clindamycin Phosphate and Benzoyl Peroxide) including clinical experience, mechanism of action, indications, dosing, efficacy, as well as compliance issues and side-effects.

Management of the patients’ expectations and compliance are crucial aspects of acne treatment. Disease chronicity and long-term treatment should be discussed at length during the initial consultation.

Since multiple factors are involved in the pathophysiology of acne, treatment that counteracts the majority of them can be expected to achieve the best results. When considering the options for reducing the P. acnes population, it is best to choose those that do not encourage resistance patterns.

Acne is a multifactorial disease of the pilosebaceous unit in the skin. Four contributing pathogenic factors need to be elucidated and include excess sebum production, follicular hyperkeratinization, colonization of the pilosebaceous unit by Propionibacterium acnes.

Clindoxyl® Gel (Stiefel) is a combination of 1% clindamycin phosphate and 5% benzoyl peroxide in a gel vehicle that is well tolerated and more efficacious than either active agent alone or the vehicle in reducing lesion counts and improving global scores in patients with moderate acne.

Update on drugs: Fluocinolone Acetonide, Hydroquinone, Tretinoin Tri-Luma®Pimecrolimus Elidel®Clindamycin, Zinc Zindaclin™ Gel Voriconazole Vfend® Imiquimod Aldara® 5% Cream

Use of medications by breast-feeding mothers is not uncommon. Information regarding the safety of common dermatological medications during lactation will be reviewed. Based on this information, treatment recommendations will be made.

Psoriasis, acne vulgaris and photoaging are common conditions. Tazarotene is a pro-drug of tazarotenic acid, a receptor-selective retinoid, which has shown efficacy in the treatment of these disorders. In the treatment of acne vulgaris, it has greater comedolytic activity than the currently available topical retinoids.